Dystonia
Dystonia (literally, "abnormal muscle tone") is a term used to describe a movement disorder involving involuntary, sustained muscle contractions. Dystonia and Parkinson's disease together are the most common movement disorders in the developed world, affecting an estimated 800,000 people in North America, and at least 90,000 people in Australia. At present, there are no known therapies that arrest the progression of these neurodegenerative diseases.
QRxPharma to Sponsor Symposium at International Association for the Study of Pain Meeting 
31 August 2010
Frost & Sullivan Recognises QRxPharma's MoxDuo® IR for Innovation in Pain Therapy
18 August 2010 [Click here to read the Frost & Sullivan Release]
QRxPharma Announces Positive Phase 2 Proof-of-Concept Data for MoxDuo® IV Pain Therapy
9 August 2010
Webcast Link: QRxPharma Presentation at Noble Financial's Equity Conference
11AM EDT, 7 June 2010 
1 June 2010
ASX Spotlight: John Holaday, Managing Director and CEO, QRxPharma 
24 May 2010
QRxPharma Successfully Completes Pivotal Phase 3 Combination Rule Study for MoxDuo® IR in Patients with Post-Surgical Pain
14 April 2010
QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo®IV
23 February 2010
QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo™ IR Dual-Opioid™ for NDA Submission
10 February 2010
BioTech Nation Podcast with Dr. Moira Gunn [mp3 Audio]
19 January 2010
QRxPharma Initiates Pivotal Phase 3 Study of MoxDuo™IR For Moderate to Severe Acute Pain
30 November 2009
QRxPharma Limited Announces A $21.6 Million Fully Underwritten Capital Raising
16 November 2009
QRxPharma Announces Completion of Strategic Alliance Deal with Liaoning Nuokang Medicines Co Ltd for the Development of Venomics Assets
20 October 2009
QRxPharma Inks Deal with Patheon for the Manufacture of MoxDuo™CR
12 October 2009
MoxDuo™ IR Demonstrates Fewer Side Effects than Percocet®
26 August 2009
QRxPharma Initiates Comparative Phase 2 Proof-of-Concept Study for MoxDuo™ IV Pain Therapy
23 July 2009
QRxPharma Successfully Completes Comparative Study for Dual-Opioid™ Pain Therapy
20 April 2009
QRxPharma Initiates Second Comparative Study for MoxDuo™ IR Dual-Opioid™ Pain Therapy
19 February 2009
QRxPharma Initiates Comparative Study for MoxDuoIR™ Dual-Opioid™ Pain Therapy
16 December 2008
QRxPharma and University of Alabama at Birmingham Collaborate on Research Program for Parkinson’s Disease
29 October 2008
FDA Accepts Streamlined Phase 3 Development Plan for Q8003IR “Dual Opioid” Pain Therapy
5 August 2008
QRxPharma Begins Trading on the International OTCQX
1 July 2008
QRxPharma Releases Additional Phase 3 Data for Q8003IR ‘Dual Opioid’ Pain Therapy
22 May 2008
QRxPharma Releases Successful Phase 3 Study Results for 'Dual Opioid' Pain Therapy
5 May 2008
Bioshares: The Commercial Context for QRxPharma’s QR8003
11 April 2008
The Commercial Context for QRxPharma’s QR8003QRxPharma Limited Interim Report for the half-year ended 31 December 2007
26 February 2008
QRxPharma Initiates Second Phase III Clinical Trial for its ‘Dual Opioid’ Pain Therapy
13 December 2007
QRxPharma Moving Rapidly with First Patients Enrolled in Phase III Clinical Trial Programme for its “Dual Opioid” Pain Therapy
The Australian Investor, November 2007
QRxPharma Doses First Patients in Phase III Clinical Trial Program for its ‘Dual Opioid’ Pain Therapy
26 November 2007
QRxPharma Annual report 2007
27 September 2007
JP Morgan Analyst Report
4 July 2007
QRxPharma Trials Recipe for Pain Relief
28 June 2007 - The Australian Financial Review
Australian firm combines with local biotech entrepreneur in U.S. venture
21 June 2007 - Washington Business Journal
QRxPharma Completes $50 Million IPO; Trading Commences on the Australian Securities Exchange
25 May 2007
- QRxPharma Limited
- 1/194 Miller Street
- North Sydney, NSW 2060
- +61 2 9492 8021
- +61 2 8920 0314 (fax)